Tone mix
Week by week 52 weeks
Share of ABBVIE INC.'s 1,239 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Mar 2, 2026 · tone +79Equities Research Analysts' Upgrades for February 28th (AAOI, ABBV, ABR, ACIU, ACMR, ADMA, ADTN, AHT, AIT, ALTG)+46
- Week of Jun 8, 2026 · tone -1Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225-37
- Week of Jan 12, 2026 · tone +55Trump administration strikes deal with AbbVie to cut costs of certain drugs+34
- Week of Feb 23, 2026 · tone +60Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential+33
- Week of Sep 28, 2026 · tone +56AbbVie Stock: Buy, Sell, or Hold in October?+27
- Week of Jul 27, 2026 · tone +2AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?-26
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about ABBVIE INC. in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 41 | +40 |
| Last 30 sessions | 153 | +42 |
| Last 90 sessions | 354 | +29 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, November 6, 2026
2 headlines, average tone +69: 2 positive, 0 neutral and 0 negative. Showing all 2.
- healthcare-digital.com · 1 outletWhat AbbVie's Oxford R&D Expansion Means for UK PharmaPositive
- www.techtimes.com · 1 outletSkyrizi and Rinvoq Cannot Prevent Gut Cells from Dying; AbbVie Paid $100M for IBD Drug That CanPositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| What AbbVie's Oxford R&D Expansion Means for UK Pharma | healthcare-digital.com | 1 | Positive |
| Skyrizi and Rinvoq Cannot Prevent Gut Cells from Dying; AbbVie Paid $100M for IBD Drug That Can | www.techtimes.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, November 5, 2026
3 headlines, average tone +66: 2 positive, 1 neutral and 0 negative. Showing all 3.
- www.themarketsdaily.com · 1 outletAbbVie (NYSE:ABBV) Price Target Raised to $338.00Positive
- www.bioxconomy.com · 1 outletNxera's gut-targeted molecule nets $1.47bn from AbbViePositive
- www.rttnews.com · 1 outletNxera Pharma Revises FY26 Financial Forecast Following $100 Mln AbbVie DealNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| AbbVie (NYSE:ABBV) Price Target Raised to $338.00 | www.themarketsdaily.com | 1 | Positive |
| Nxera's gut-targeted molecule nets $1.47bn from AbbVie | www.bioxconomy.com | 1 | Positive |
| Nxera Pharma Revises FY26 Financial Forecast Following $100 Mln AbbVie Deal | www.rttnews.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, November 4, 2026
4 headlines, average tone +71: 3 positive, 1 neutral and 0 negative. Showing all 4.
- 247wallst.com · 1 outletAbbVie Hit a New High After Earnings. There's More Upside Left.Positive
- www.bioxconomy.com · 1 outletBrise and AbbVie reveal $757m migraine licensing pactPositive
- www.manilatimes.net · 1 outletNxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel DiseasePositive
- www.themarketsdaily.com · 1 outletAbbVie (NYSE:ABBV) Issues FY 2026 Earnings GuidanceNeutral
Show the table · 4 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| AbbVie Hit a New High After Earnings. There's More Upside Left. | 247wallst.com | 1 | Positive |
| Brise and AbbVie reveal $757m migraine licensing pact | www.bioxconomy.com | 1 | Positive |
| Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease | www.manilatimes.net | 1 | Positive |
| AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
6 headlines, average tone +34: 3 positive, 2 neutral and 1 negative. Showing all 6.
- www.morningstar.com · 1 outletAbbVie Earnings: Raising Our Fair Value Estimate With Significant Pipeline ProgressPositive
- www.tickerreport.com · 1 outletLeerink Partners Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) StockPositive
- www.manilatimes.net · 1 outletBrise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine TherapiesPositive
- www.law360.com · 1 outletTeva, AbbVie To Face Trial Over Niaspan Pay-For-Delay ClaimsNegative
- www.themarketsdaily.com · 1 outletAbbVie Inc. $ABBV Shares Acquired by VCI Wealth Management LLCNeutral
- www.fool.com · 1 outletAbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027?Neutral
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| AbbVie Earnings: Raising Our Fair Value Estimate With Significant Pipeline Progress | www.morningstar.com | 1 | Positive |
| Leerink Partners Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock | www.tickerreport.com | 1 | Positive |
| Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies | www.manilatimes.net | 1 | Positive |
| Teva, AbbVie To Face Trial Over Niaspan Pay-For-Delay Claims | www.law360.com | 1 | Negative |
| AbbVie Inc. $ABBV Shares Acquired by VCI Wealth Management LLC | www.themarketsdaily.com | 1 | Neutral |
| AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy for 2027? | www.fool.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
20 headlines, average tone +27: 8 positive, 10 neutral and 2 negative. The 8 most widely carried stories are listed; the table holds all 20.
- www.aol.com · 3 outletsIs AbbVie a Buy After Its Latest Earnings Report?Neutral
- 247wallst.com · 2 outlets$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in DividendsPositive
- www.fool.com · 2 outletsPrediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's ComboPositive
- seekingalpha.com · 1 outletHealthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth (ABBV:NYSE)Positive
- www.investors.com · 1 outletAbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats AgainPositive
- finchannel.com · 1 outletAbbVie lifts earnings outlook and dividend after Q3 growthPositive
- www.themarketsdaily.com · 1 outletAbbVie (NYSE: ABBV) raises its profit outlook as immunology sales jump 16.3%Positive
- www.rttnews.com · 1 outletAbbVie Raises FY26 Adj. EPS Outlook; Boost Dividend 5.2%Positive
Show the table · 20 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Is AbbVie a Buy After Its Latest Earnings Report? | www.aol.com | 3 | Neutral |
| $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends | 247wallst.com | 2 | Positive |
| Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo | www.fool.com | 2 | Positive |
| Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growth (ABBV:NYSE) | seekingalpha.com | 1 | Positive |
| AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again | www.investors.com | 1 | Positive |
| AbbVie lifts earnings outlook and dividend after Q3 growth | finchannel.com | 1 | Positive |
| AbbVie (NYSE: ABBV) raises its profit outlook as immunology sales jump 16.3% | www.themarketsdaily.com | 1 | Positive |
| AbbVie Raises FY26 Adj. EPS Outlook; Boost Dividend 5.2% | www.rttnews.com | 1 | Positive |
| AbbVie outlines 2026 adjusted EPS of $13.95-$13.99 while raising expected revenue to $67.8B (NYSE:ABBV) | seekingalpha.com | 1 | Positive |
| Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals | www.rttnews.com | 1 | Negative |
| Teva, AbbVie To Face Trial Over Niaspan Pay-For-Delay Claims | www.law360.com | 1 | Negative |
| ABBV - AbbVie Inc Analysis | Morningstar | www.morningstar.com | 1 | Neutral |
| AbbVie Inc. $ABBV Stake Lowered by ProShare Advisors LLC | www.themarketsdaily.com | 1 | Neutral |
| 25,704 AbbVie Inc. $ABBV Shares Bought by Vise Technologies Inc. | www.themarketsdaily.com | 1 | Neutral |
| Partners Wealth Management LLC Buys 2,631 Shares of AbbVie Inc. $ABBV | www.themarketsdaily.com | 1 | Neutral |
| What AbbVie (ABBV) Said on Its Q3 Earnings Call | www.dailypolitical.com | 1 | Neutral |
| Anika Therapeutics (NASDAQ:ANIK) and AbbVie (NYSE:ABBV) Financial Analysis | www.dailypolitical.com | 1 | Neutral |
| AbbVie: 3 Key Takeaways for Long-Term Investors | www.fool.com | 1 | Neutral |
| AbbVie (ABBV) Q3 2026 Earnings Call Transcript | www.fool.com | 1 | Neutral |
| CDs Offer Fixed Interest. AbbVie Offers a Growing Dividend. Which Should Retirees Choose? | 247wallst.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about ABBVIE INC., not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.